NCT02003534已完成4 期
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 376
- 主要终点
- Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
研究概览
简要总结
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of open-angle glaucoma or ocular hypertension
排除标准
- •Used Alphagan® in previous 3 months
研究组 & 干预措施
0.15% Brimonidine Tartrate
Experimental
0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
干预措施: 0.15% Brimonidine Tartrate (Drug)
结局指标
主要结局
Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
时间窗: Baseline, Month 3
IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric SubjectsOcular RednessNCT01675609Eye Therapies, LLC57
已完成
3 期
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOcular HypertensionNCT00061529Alcon Research
已完成
3 期
Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00168363Allergan207
已完成
不适用
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal EyesHealthyNCT00413751Walter Reed Army Medical Center20
已完成
3 期
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00652483Allergan433